Mucopolysaccharidosis Type Vi – 2018-2028 –

The “Epiomic
Epidemiology Series: Mucopolysaccharidosis Type Vi Forecast In 30 Major
Markets 2018-2028” report has been added to’s

This report provides the current prevalent population for MPS VI across
30 Major Markets split by gender and 5-year age cohort. In addition to
the current prevalence, the report provides an overview of the risk
factors, diagnosis and prognosis of the disease, along with specific
variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, MPS VI
patients grouped by disease severity and comorbidities have been
quantified and presented alongside the overall prevalence figures. These
sub-populations within the main disease are also included at a country
level across the 10-year forecast snapshot.

Markets Featured:

Main symptoms and co-morbidities of MPS VI include:

Reasons to buy:

Key Topics Covered:

For more information about this report visit

View source version on

Leave a Comment